Boehringer Ingelheim
For Healthcare Professionals
Nintedanib

Read more
Nintedanib_1

Read more

INBUILD® Trial Population and Baseline Medications

15/03/2023 | Author: Boehringer Ingelheim

Document ID: PC-SG-101827

EFFICACY

A1-R101||A2-R101||INBUILD® Trial Efficacy (RA-ILD Subgroup Analysis) by Dr E. Volkmann
FSIN||Progressive Pulmonary Fibrosis (PPF) - Diagnosis and Treatment in the ATS/ERS/JRS/ALAT Guideline
SGOFV2023COM||INBUILD® Trial Efficacy (autoimmune ILD patients)
SGOFV2023COM||INBUILD® Trial Population and Baseline Medications
SGOFV2022COM||The key to managing progression in SSc-ILD patients
Listen to our experts share their insights on why INBUILD® is an important study for patients with PF-ILD
SGOFV2023COM||Largest prospective Phase III clinical trial in patients with SSc-ILD
OFEV® across different disease severities
OFEV® and acute IPF exacerbations
OFEV® in IPF patients with FVC ≤50% predicted
Progressive Pulmonary Fibrosis: Diagnosis & Treatment in the ATS/ERS/JRS/ALAT Guideline
Progressive Pulmonary Fibrosis: focus on autoimmune ILDs
Mortality data in IPF
OFEV® is the first and only approved therapy for PF-ILD
OFEV® reduces the risk of acute exacerbations as seen in INBUILD®

RELATED CONTENT